Company* (Country; Symbol) |
Company* (Country; Symbol) |
Product |
Terms/Details (Date) |
|
| |||
Acambis plc(UK; ACAM) | Bharat Biotech International Ltd.* (India) | Manufacturing and marketing deal relating to Acambis' ChimeriVax-JE vaccine against Japanese encephalitis | Bharat will be responsible for end-stage fill/finish processing and would market the vaccine in India and neighboring countries; terms were not disclosed (11/8) |
| |||
Cell Genesys Inc. (CEGE) | Genzyme Corp. (GENZ) | Genzyme acquired CellGenesys' manufacturing operation in San Diego to support its gene therapy programs |
Cell Genesys gets $3.2M in cash in the deal; most of the approximately 40 employees there have become Genzyme employees |
| |||
Cobra Bio-manufacturing plc (UK; AIM:CBF) |
Advaxis Inc. (OTC BB:ADXS) | Cobra will manufacture experimental and commercial supplies of Advaxis' Listeria cancer vaccines | The deal supersedes a prior agreement; the initial product will be the Lovaxin C vaccine; terms of the deal were not disclosed (11/7) |
| |||
CombiMatrix Group (CBMX) | Cold Spring Biotech* (China) |
Cold Spring will distribute CombiMatrix products and services in China, Taiwan and Hong Kong | Cold Spring will market CustomArrays and CatalogArrays under undisclosed terms (1/12) |
| |||
CombiMatrix Group (CBMX) |
Novavax Inc. (NVAX) |
Collaboration to develop an improved process for producing Novavax's H5N1 bird flu vaccine | They will use CombiMatrix's technique for in-process monitoring of vaccine production in the effort, terms of which were not disclosed (11/9) |
| |||
CombiMatrix Group (CBMX) | CyGenics Ltd. (Australia; ASX:CYN) | Nonexclusive deal for the distribution of CombiMatrix products and services | CyGenics subsidiary Cell Sciences Pte. Ltd. will sell CustomArrays and CatalogArrays in Singapore, Malaysia, Thailand, the Philippines, Hong Kong and Indonesia (11/30) |
| |||
Deltagen Inc. (PK:DGEN) | Charles River Laboratories International Inc. (NYSE:CRL) | Charles River will exclusively supply Deltagen's knockout mice repository | Charles River will be the sole-source provider of the materials on a worldwide basis (1/9) |
| |||
Dendritic Nano-technologies Inc. * | Lumera Corp. (LMRA) |
Deal to develop surface chemistries suitable for applications on Lumera's label-free array reader | The deal focuses on Lumera's Proteomic-Processor product; terms were not disclosed (11/10) |
| |||
Gen-Probe Inc. (GPRO) |
Molecular Profiling Institute Inc.* | Deal to accelerate development of cancer diagnostic products from Gen-Probe | Molecular Profiling will help validate and commercialize up to four products, and provide certain contract research services; Gen-Probe acquired a minority interest in Molecular Profiling (10/26) |
| |||
GenTel BioSurfaces Inc.* | Abnova Corp.* (Taiwan) |
Deal to develop custom multiplex immunoassays | GenTel's PATH Protein Microarray System will be used in the effort; terms of the deal were not disclosed (11/9) |
| |||
Omnia Biologics Inc.* |
Lentigen Inc.* |
Nonexclusive deal regarding the manufacturing of clinical-and research-grade lentiviral vectors |
Each may refer clients to the other party for its respective services; additional terms were not disclosed (12/6) |
| |||
Paladin Labs Inc. (Canada; TSE:PLB) |
Nuvo Research Inc. (Canada; TSE:NRI) |
Paladin acquired additional rights in Canada to the oseoarthritis product Pennsaid |
Paladin subsidiary Squire Pharmaceuticals Inc. is making an up-front payment to Nuvo, providing ongoing royalties, and investing C$0.5M through a three-year convertible note (1/17) |
| |||
Pluristem Life Systems Inc. (Israel; OTC BB:PLRS) |
Biological Industries Ltd.* (Israel) |
Deal for the global distribution of joint serum-free media products designed for hematopoietic and mesenchymal stem cells |
They will use Pluristem's PluriX bioreactor in the effort; Pluristem gets a license fee equal to 5% of sales of serum-free media for seven years (10/20) |
| |||
Strand Life Sciences Pvt. Ltd.* (India) | Stratagene Corp. (STGN) |
Deal to develop a suite of next-generation bioinformatics software tools | Stratagene will exclusively market resulting products, which will use Strand's Avadis technology (12/8) |
| |||
Third Wave Technologies Inc. (TWTI) |
Genzyme Corp. (GENZ) |
They formed a preferred marketing agreement for Third Wave's Invader UGT1A1 Molecular Assay |
Genzyme Genetics will provide testing for colorectal cancer patients in North America who may or are taking the cancer drug Camptosar; terms were not disclosed (10/27) |
| |||
Three Rivers Pharmaceuticals LLC* | Samaritan Pharmaceuticals Inc. (AMEX:LIV) | Samaritan got rights to distribute the amphotericin B product Amphocil in Greece and Cyprus | Amphocil is indicated for the treatment of invasive aspergillosis; terms of the deal were not disclosed (12/14) |
| |||
Tripos Inc. (TRPS) |
InforSense Ltd.* (UK) |
Companies will integrate drug discovery platforms |
Terms of the deal were not disclosed (12/12) |
|
| |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; | |||
